Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Prevention and risk

Reviewed as evidence on: Menopause timing / hormone therapy (estrogen-only) and dementia risk and AD neuropathology 7 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Risk, prevention and care in population studies

Plain-language summary

No significant association was found between MHT use and risk of mild cognitive impairment or dementia. Subgroup analyses by timing, duration, and type of MHT showed no significant effects.

What this study adds

Evidence grade: Moderate

This is a pooled review of 1,016,055 participants. This meta-analysis found no significant association between menopause hormone therapy use and risk of mild cognitive impairment or dementia. Its stated limit: Only one RCT; observational studies vary in how they captured hormone use; no data on early menopause or premature ovarian insufficiency; pooled effect sizes not given in the abstract.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Melville, M., He, L., Desai, R., Nyamayaro, P., Fox, C., Kothari, K. U., et al. (2025). Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. The Lancet Healthy Longevity. https://doi.org/10.1016/j.lanhl.2025.100803

Vancouver

Melville M, He L, Desai R, Nyamayaro P, Fox C, Kothari KU, et al. Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. The Lancet Healthy Longevity. 2025. doi:10.1016/j.lanhl.2025.100803. PMID: 41448220.

BibTeX

@article{melville2025-41448220,
  author  = {Melville, M. and He, L. and Desai, R. and Nyamayaro, P. and Fox, C. and Kothari, K. U. and Condron, P. and Miao, M. and Hickey, M. and Spector, A.},
  title   = {{Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis}},
  journal = {The Lancet Healthy Longevity},
  year    = {2025},
  doi     = {10.1016/j.lanhl.2025.100803},
  pmid    = {41448220},
  url     = {https://doi.org/10.1016/j.lanhl.2025.100803}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 10 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This meta-analysis found no significant association between menopause hormone therapy use and risk of mild cognitive impairment or dementia. Subgroup analyses by timing, duration and type of therapy also showed no significant effects.

Study details

Limitations

Only one RCT; observational studies vary in how they captured hormone use; no data on early menopause or premature ovarian insufficiency; pooled effect sizes not given in the abstract.

How this study scored 66/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 1 of 4; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 65 of the 98 points it could be judged on, which is 66 of 100. Total 66 of 100.65 of the 98 points we could judge = 66 of 100

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it. We have no data on free to read, so that was left out: it earned 65 of the 98 points we could judge it on, which is 66 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet Healthy Longevity)
Journal's citation record 1 / 4 The Lancet Healthy Longevity: journal h-index 78 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 4 / 4 1,016,055 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 3 / 7 Cited 22 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 4.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Aimee E Spector: h-index 59 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 9 institution(s) in 5 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41448220)
Free to read — / 2 Access not recorded — left out of this score
Points 65 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 65 of the 98 points we could judge it on is 66 out of 100.
Total 66 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention and risk from nearby years

Also tagged “menopause-hrt-and-dementia”

7 studies in the library carry the topic tag “menopause-hrt-and-dementia”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 7 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →